Quick Answer
AYTU BIOPHARMA, INC reported Net Income Loss of -$13.56 million for the year ending 2025.
- AYTU BIOPHARMA, INC showed an increase of +14.4% in Net Income Loss from 2024 to 2025.
- This data is from AYTU BIOPHARMA, INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2006 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 20 years of available data (2006 to 2025), AYTU BIOPHARMA, INC's Net Income Loss has declined by 19,153.0%.
- Historical annual values: Fiscal year 2025: -$13.56 million | Fiscal year 2024: -$15.84 million | Fiscal year 2023: -$17.05 million | Fiscal year 2022: -$108.78 million | Fiscal year 2021: -$58.29 million | Fiscal year 2020: -$13.62 million | Fiscal year 2019: -$27.13 million | Fiscal year 2018: -$10.19 million | Fiscal year 2017: -$22.51 million | Fiscal year 2016: -$28.18 million | Fiscal year 2015: -$7.72 million | Fiscal year 2014: -$5.58 million | Fiscal year 2013: -$57.3 thousand | Fiscal year 2012: -$59.7 thousand | Fiscal year 2011: -$136.8 thousand | Fiscal year 2010: -$60.3 thousand | Fiscal year 2009: -$58.9 thousand | Fiscal year 2008: -$57.2 thousand | Fiscal year 2007: -$49.0 thousand | Fiscal year 2006: -$70.4 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: